Recent Development Technique in Management of Cancer

Year : 2024 | Volume : | : | Page : –
By

Shruti Morankar

Gangadhar Bhaurao Magar

Abstract

Cancer develops when a change in one’s genetic makeup leads to the development of tumour cells. These clusters of malignant cells eventually develop into tumours. Tumors can shed cancerous cells, which can then travel through the lymphatic system or the circulatory system to other organs. In the medical field, this occurrence is referred to as metastasis. Cancer cells proliferate even when they have no instructions to do so. Despite the notable advancements in medical technology, such as stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-based therapy, traditional treatment methods like surgery, chemotherapy, and radiation remain prevalent. These traditional procedures continue to be utilized due to their established efficacy, widespread availability, and proven track record in treating various medical conditions across diverse patient populations. Today, oncology practises are centred on developing safe and efficient nanomedicines for the treatment of cancer. Nanoparticles have provided new diagnostic and therapeutic options, and stem cell treatment has shown extraordinary efficacy in regenerating and repairing sick or damaged tissues, including those at the main and metastatic cancer foci.

Keywords: Malignancy, Ablation therapy, Ferroptosis based therapy, Radionics, Apoptosis, Sonodynamic based therapy.

How to cite this article: Shruti Morankar, Gangadhar Bhaurao Magar. Recent Development Technique in Management of Cancer. Research & Reviews: Journal of Oncology and Hematology. 2024; ():-.
How to cite this URL: Shruti Morankar, Gangadhar Bhaurao Magar. Recent Development Technique in Management of Cancer. Research & Reviews: Journal of Oncology and Hematology. 2024; ():-. Available from: https://journals.stmjournals.com/rrjooh/article=2024/view=137089


References

  1. Olsson M, Zhivotovsky B. Caspases and cancer. Cell Death & Differentiation. 2011 Sep;18(9):1441-9.
  2. Weinberg, R.A., 1996. How cancer arises. Scientific American, 275(3), pp.62-70.
  3. Mantyh PW. Cancer pain: causes, consequences and therapeutic opportunities. Wall and Melzack’s textbook of pain. 2006:1087-97.
  4. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. JNCI: Journal of the National Cancer Institute. 1981 Jun 1;66(6):1192-308.
  5. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Reviews on environmental health. 2008 Jan;23(1):1-38.
  6. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature medicine. 2004 Aug 1;10(8):789-99.
  7. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012 Jun 21;486(7403):400-4.
  8. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23;505(7484):495-501.
  9. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23;505(7484):495-501.
  10. Wodarz, Andreas, and Inke Näthke. “Cell polarity in development and cancer.” Nature cell biology 9.9 (2007): 1016-1024.
  11. MOHS, FREDERIC E., and THEODORE G. LATHROP. “Modes of spread of cancer of skin.” AMA Archives of Dermatology and Syphilology 66.4 (1952): 427-439.
  12. Kirchner, J. A., and D. Carter. “Intralaryngeal barriers to the spread of cancer.” Acta Oto-Laryngologica 103.5-6 (1987): 503-513.
  13. Brossart, P., 2020. The Role of Antigen Spreading in the Efficacy of ImmunotherapiesEpitope Spreading in Cancer Immunotherapy. Clinical Cancer Research, 26(17), pp.4442-4447.
  14. Kapałczyńska, M., Kolenda, T., Przybyła, W., Zajączkowska, M., Teresiak, A., Filas, V., Ibbs, M., Bliźniak, R., Łuczewski, Ł. and Lamperska, K., 2018. 2D and 3D cell cultures–a comparison of different types of cancer cell cultures. Archives of Medical Science, 14(4), pp.910-919.
  15. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. The Journal of clinical investigation. 2005 Jun 1;115(6):1503-21.
  16. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators*. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Annals of internal medicine. 2008 May 20;148(10):728-36.
  17. Saunders, C.M., 1967. The care of the terminal stages of cancer. Annals of the Royal College of Surgeons of England, 41(Suppl), p.162.
  18. Qi, F., Zhao, L., Zhou, A., Zhang, B., Li, A., Wang, Z. and Han, J., 2015. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Bioscience trends, 9(1), pp.16-34.
  19. McMahon, K.W., Karunasena, E. and Ahuja, N., 2017. The roles of DNA methylation in the stages of cancer. Cancer journal (Sudbury, Mass.), 23(5), p.257.
  20. Rami-Porta, R., Crowley, J.J. and Goldstraw, P., 2009. Review the revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg, 15(1), p.5.
  21. Puppa, G., Sonzogni, A., Colombari, R. and Pelosi, G., 2010. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Archives of pathology & laboratory medicine, 134(6), pp.837-852.
  22. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA: a cancer journal for clinicians. 2005 Jul;55(4):242-58.
  23. Lababede, O., Meziane, M. and Rice, T., 2011. of the cancer staging manual and stage grouping of lung cancer: Quick reference chart and diagrams. Chest, 139(1), pp.183-189.
  24. Detterbeck, F.C., Boffa, D.J. and Tanoue, L.T., 2009. The new lung cancer staging system. Chest, 136(1), pp.260-271.
  25. Hajj, C. and Goodman, K.A., 2015. Role of radiotherapy and newer techniques in the treatment of GI cancers. Journal of Clinical Oncology, 33(16), pp.1737-1744.
  26. Lipsett, M.B., 1960. Newer techniques and some problems in cooperative group studies. In Conference on Experimental Clinical Cancer Chemotherapy (Vol. 18, p. 277). National Cancer Institute.
  27. Schnitt, Stuart J. “Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.” Modern pathology 23 (2010): S60-S64.
  28. Risk factors in the development of stem cell therapy. Journal of translational medicine, 9(1), pp.1-14.olecular taxonomy. Modern pathology, 23(2), pp.S60-S64.
  29. Biehl, J.K. and Russell, B., 2009. Introduction to stem cell therapy. The Journal of cardiovascular nursing, 24(2), p.98.
  30. Sagar, J., Chaib, B., Sales, K., Winslet, M. and Seifalian, A., 2007. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer cell international, 7(1), pp.1-11.
  31. Jenq, R.R. and Van den Brink, M.R., 2010. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nature Reviews Cancer, 10(3), pp.213-221.
  32. Vasir, J.K. and Labhasetwar, V., 2005. Targeted drug delivery in cancer therapy. Technology in cancer research & treatment, 4(4), pp.363-374.
  33. Pérez-Herrero, E. and Fernández-Medarde, A., 2015. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European journal of pharmaceutics and biopharmaceutics, 93, pp.52-79.
  34. Jain, K. K. “Targeted drug delivery for cancer.” Technology in cancer research & treatment 4.4 (2005): 311-313.
  35. Roth, Jack A., and Richard J. Cristiano. “Gene therapy for cancer: what have we done and where are we going?.” Journal of the National Cancer Institute 89.1 (1997): 21-39.
  36. Schmitt, Thomas M., Gunnar B. Ragnarsson, and Philip D. Greenberg. “T cell receptor gene therapy for cancer.” Human gene therapy 20.11 (2009): 1240-1248.
  37. Rosenberg, Steven A. “Gene therapy for cancer.” Jama 268.17 (1992): 2416-2419.
  38. Mauri, G., Nicosia, L., Xu, Z., Di Pietro, S., Monfardini, L., Bonomo, G., Varano, G.M., Prada, F., Della Vigna, P. and Orsi, F., 2018. Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer. The British journal of radiology, 91(xxxx), p.20170641.
  39. Friedman, M., Mikityansky, I., Kam, A., Libutti, S.K., Walther, M.M., Neeman, Z., Locklin, J.K. and Wood, B.J., 2004. Radiofrequency ablation of cancer. Cardiovascular and interventional radiology, 27(5), pp.427-434.
  40. Ashikbayeva, Z., Tosi, D., Balmassov, D., Schena, E., Saccomandi, P. and Inglezakis, V., 2019. Application of nanoparticles and nanomaterials in thermal ablation therapy of cancer. Nanomaterials, 9(9), p.1195.
  41. Block, K.I., 2004. Antioxidants and cancer therapy: furthering the debate. Integrative Cancer Therapies, 3(4), pp.342-348.
  42. Valadez-Vega, Carmen, et al. “The role of natural antioxidants in cancer disease.” Oxidative stress and chronic degenerative diseases-A role for antioxidants. IntechOpen, 2013.
  43. Brigger, I., Dubernet, C. and Couvreur, P., 2012. Nanoparticles in cancer therapy and diagnosis. Advanced drug delivery reviews, 64, pp.24-36.
  44. Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M. and Aghebati‐Maleki, L., 2020. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. Journal of cellular physiology, 235(3), pp.1962-1972.
  45. Tansley, David V. Radionics & the subtle anatomy of man. Random House, 2011.
  46. Andreadis, E., Saliangas, K., Economou, A., Nikoloudis, N., Manna, I., Prodromou, K., Siminou, S. and Chrissidis, T., 2004. Application of radionics on primary and metastatic tumours of the liver. Techniques in Coloproctology, 8(1), pp.s184-s186.
  47. Wang, X., Zhong, X., Liu, Z. and Cheng, L., 2020. Recent progress of chemodynamic therapy-induced combination cancer therapy. Nano Today, 35, p.100946.
  48. Li, S.L., Jiang, P., Jiang, F.L. and Liu, Y., 2021. Recent advances in nanomaterial‐based nanoplatforms for chemodynamic cancer therapy. Advanced Functional Materials, 31(22), p.2100243.
  49. Chen, H., Zhou, X., Gao, Y., Zheng, B., Tang, F. and Huang, J., 2014. Recent progress in development of new sonosensitizers for sonodynamic cancer therapy. Drug discovery today, 19(4), pp.502-509.
  50. Xu, M., Zhou, L., Zheng, L., Zhou, Q., Liu, K., Mao, Y. and Song, S., 2021. Sonodynamic therapy-derived multimodal synergistic cancer therapy. Cancer letters, 497, pp.229-242.
  51. Umemura, S., Kawabata, K., Sasaki, K., Yumita, N., Umemura, K. and Nishigaki, R., 1996. Recent advances in sonodynamic approach to cancer therapy. Ultrasonics Sonochemistry, 3(3), pp.S187-S191.
  52. Shen, Z., Song, J., Yung, B.C., Zhou, Z., Wu, A. and Chen, X., 2018. Emerging strategies of cancer therapy based on ferroptosis. Advanced Materials, 30(12), p.1704007.
  53. Michael, M. and Tannock, I.F., 1998. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Cmaj, 158(13), pp.1727-1734.
  54. Coffey, J.C., Wang, J.H., Smith, M.J.F., Bouchier-Hayes, D., Cotter, T.G. and Redmond, H.P., 2003. Excisional surgery for cancer cure: therapy at a cost. The lancet oncology, 4(12), pp.760-768.
  55. Hayes, D.F., 2015. Biomarker validation and testing. Molecular oncology, 9(5), pp.960-966.
  56. Lim, C., Tsao, M.S., Le, L.W., Shepherd, F.A., Feld, R., Burkes, R.L., Liu, G., Kamel-Reid, S., Hwang, D., Tanguay, J. and da Cunha Santos, G., 2015. Biomarker testing and time to treatment decision in Kuhle, C.L., Kapoor, E., Sood, R., Thielen, J.M., Jatoi, A. and Faubion, S.S., 2016.
  57. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas, 92, pp.86-96.patients with advanced nonsmall-cell lung cancer. Annals of Oncology, 26(7), pp.1415-1421.
  58. Abraham, J., Ocen, J. and Staffurth, J., 2022. Hormonal therapy for cancer. Medicine.
  59. Kirkwood, J.M., Butterfield, L.H., Tarhini, A.A., Zarour, H., Kalinski, P. and Ferrone, S., 2012. Immunotherapy of cancer in 2012. CA: a cancer journal for clinicians, 62(5), pp.309-335.
  60. Melief, Cornelis JM, et al. “Strategies for immunotherapy of cancer.” (2000): 235-282.
  61. Dougherty, T.J., Gomer, C.J., Henderson, B.W., Jori, G., Kessel, D., Korbelik, M., Moan, J. and Peng, Q., 1998. Photodynamic therapy. JNCI: Journal of the national cancer institute, 90(12), pp.889-905.
  62. Agostinis, P., Berg, K., Cengel, K.A., Foster, T.H., Girotti, A.W., Gollnick, S.O., Hahn, S.M., Hamblin, M.R., Juzeniene, A., Kessel, D. and Korbelik, M., 2011. Photodynamic therapy of cancer: an update. CA: a cancer journal for clinicians, 61(4), pp.250-281.
  63. Hahn GM. Hyperthermia and cancer. Springer Science & Business Media; 2012 Dec 6.
  64. Baronzio, Gian F., and E. Dieter Hager, eds. Hyperthermia in cancer treatment: a primer. Springer Science & Business Media, 2008.
  65. Wan, G.Y., Liu, Y., Chen, B.W., Liu, Y.Y., Wang, Y.S. and Zhang, N., 2016. Recent advances of sonodynamic therapy in cancer treatment. Cancer biology & medicine, 13(3), p.325.
  66. Zhang, Y., Li, M., Gao, X., Chen, Y. and Liu, T., 2019. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. Journal of hematology & oncology, 12(1), pp.1-13.
Ahead of Print Subscription Review Article
Volume
Received January 3, 2024
Accepted March 7, 2024
Published March 30, 2024
Views: 28